Response to: 'Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'' by Westhoff
et al
Ann Rheum Dis
.
2021 Oct;80(10):e163.
doi: 10.1136/annrheumdis-2021-220764.
Epub 2021 Jul 16.
Authors
Michael Bonelli
1
,
Daniel Aletaha
2
Affiliations
1
Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
2
Division of Rheumatology, Medical University of Vienna, Vienna, Austria daniel.aletaha@meduniwien.ac.at.
PMID:
34272251
DOI:
10.1136/annrheumdis-2021-220764
No abstract available
Keywords:
COVID-19; rituximab; vaccination.
Publication types
Letter
Comment
MeSH terms
COVID-19 Vaccines
COVID-19*
Humans
Immunity, Cellular
Rituximab
SARS-CoV-2*
Vaccination
Substances
COVID-19 Vaccines
Rituximab